Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EMBCNASDAQ:IRMDNASDAQ:RXSTNYSEAMERICAN:STXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMBCEmbecta$9.98-4.0%$11.78$9.98▼$21.48$583.26M1.24469,718 shs540,584 shsIRMDIradimed$60.36-0.7%$52.80$41.71▼$63.29$767.48M0.9143,279 shs58,418 shsRXSTRxSight$14.92-2.2%$15.58$12.53▼$60.81$606.30M1.29699,597 shs533,133 shsSTXSStereotaxis$2.24-2.2%$1.95$1.54▼$2.72$189.80M1.54357,338 shs134,124 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMBCEmbecta-1.98%-1.42%-16.53%-19.25%-19.00%IRMDIradimed+1.66%+17.65%+16.21%+16.01%+42.14%RXSTRxSight-3.48%-5.22%+4.23%-40.30%-73.24%STXSStereotaxis0.00%+9.05%+15.08%+18.04%+18.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMBCEmbecta4.8591 of 5 stars3.25.03.30.02.73.33.8IRMDIradimed4.7817 of 5 stars2.53.02.54.43.93.31.9RXSTRxSight2.9842 of 5 stars4.21.00.00.03.12.50.6STXSStereotaxis0.8604 of 5 stars0.03.00.00.00.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMBCEmbecta 2.33Hold$19.3393.72% UpsideIRMDIradimed 3.00Buy$72.0019.28% UpsideRXSTRxSight 2.30Hold$37.90154.02% UpsideSTXSStereotaxis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest STXS, IRMD, RXST, and EMBC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/19/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $25.004/15/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/9/2025RXSTRxSightUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$45.00 ➝ $16.004/4/2025RXSTRxSightJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Underweight$40.00 ➝ $17.004/3/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$35.00 ➝ $22.004/3/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$36.00 ➝ $22.004/3/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMBCEmbecta$1.08B0.54$2.31 per share4.32($13.23) per share-0.75IRMDIradimed$75.15M10.21$1.50 per share40.12$5.66 per share10.66RXSTRxSight$148.31M4.09N/AN/A$4.47 per share3.34STXSStereotaxis$26.77M7.09N/AN/A$0.20 per share11.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMBCEmbecta$78.30M$0.909.983.250.785.25%-19.22%11.92%8/8/2025 (Estimated)IRMDIradimed$19.23M$1.5540.2430.18N/A26.26%24.12%21.20%7/30/2025 (Estimated)RXSTRxSight-$48.61M-$0.67N/AN/AN/A-23.92%-14.00%-12.51%8/4/2025 (Estimated)STXSStereotaxis-$20.71M-$0.28N/AN/AN/A-85.79%-162.54%-51.26%8/11/2025 (Estimated)Latest STXS, IRMD, RXST, and EMBC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMBCEmbecta$0.606.01%N/A66.67%N/AIRMDIradimed$0.681.13%N/A43.87%1 YearsRXSTRxSightN/AN/AN/AN/AN/ASTXSStereotaxisN/AN/AN/AN/AN/ALatest STXS, IRMD, RXST, and EMBC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/20255/5/2025IRMDIradimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMBCEmbectaN/A2.241.67IRMDIradimedN/A9.217.82RXSTRxSightN/A12.6711.71STXSStereotaxisN/A1.390.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMBCEmbecta93.83%IRMDIradimed92.34%RXSTRxSight78.78%STXSStereotaxis45.35%Insider OwnershipCompanyInsider OwnershipEMBCEmbecta0.42%IRMDIradimed36.80%RXSTRxSight9.36%STXSStereotaxis18.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMBCEmbecta1,90058.44 million57.89 millionOptionableIRMDIradimed11012.72 million7.97 millionOptionableRXSTRxSight22040.64 million36.53 millionOptionableSTXSStereotaxis13084.73 million69.04 millionNot OptionableSTXS, IRMD, RXST, and EMBC HeadlinesRecent News About These CompaniesStereotaxis shareholders approve board nominees and auditorMay 21, 2025 | investing.comEarnings call transcript: Stereotaxis Q1 2025 reports stable EPS, revenue growthMay 14, 2025 | uk.investing.comStereotaxis, Inc. (AMEX:STXS) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comLagoda Investment Management L.P. Purchases 295,700 Shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS)May 14, 2025 | marketbeat.comStereotaxis, Inc.: Stereotaxis Reports 2025 First Quarter Financial ResultsMay 14, 2025 | finanznachrichten.deStereotaxis Inc (STXS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...May 14, 2025 | finance.yahoo.comStereotaxis reiterates double-digit revenue growth outlook for 2025 as recurring revenue and MAGiC adoption rampMay 13, 2025 | msn.comStereotaxis, Inc. (STXS) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comStereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comStereotaxis Reports 2025 First Quarter Financial ResultsMay 12, 2025 | globenewswire.comStereotaxis Inc (STXS) Q1 2025: Everything You Need to Know Ahead of EarningsMay 10, 2025 | finance.yahoo.comStereotaxis (STXS) to Release Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comStereotaxis to Showcase GenesisX Robotic System at Heart Rhythm Symposium 2025April 23, 2025 | nasdaq.comStereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025April 22, 2025 | globenewswire.comStereotaxis to feature first-ever live demo of GenesisX Robotic SystemApril 21, 2025 | markets.businessinsider.comStereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025April 21, 2025 | globenewswire.comStereotaxis management to meet virtually with Lake StreetApril 1, 2025 | markets.businessinsider.com3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025March 26, 2025 | zacks.comNvidia’s Support Boosts Stereotaxis (STXS) in Advancing Robotic SurgeryMarch 24, 2025 | msn.comStereotaxis gains support from NVIDIA for AI roboticsMarch 21, 2025 | uk.investing.comStereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?March 21, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTXS, IRMD, RXST, and EMBC Company DescriptionsEmbecta NASDAQ:EMBC$9.98 -0.42 (-4.04%) Closing price 04:00 PM EasternExtended Trading$10.04 +0.05 (+0.55%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Iradimed NASDAQ:IRMD$60.36 -0.42 (-0.69%) Closing price 04:00 PM EasternExtended Trading$60.64 +0.28 (+0.46%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.RxSight NASDAQ:RXST$14.92 -0.34 (-2.23%) Closing price 04:00 PM EasternExtended Trading$14.92 +0.01 (+0.03%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Stereotaxis NYSEAMERICAN:STXS$2.24 -0.05 (-2.18%) Closing price 04:10 PM EasternExtended Trading$2.22 -0.02 (-0.67%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
